Novel hormonal therapies in the management of advanced prostate cancer: Extrapolating Asian findings to Southeast Asia
Document Type
Article
Publication Date
1-6-2023
Abstract
There is a paucity of information on the use of novel hormonal agents in Southeast Asian patients. We reviewed the clinical roles of novel hormonal therapy (NHT), namely abiraterone acetate (AA), enzalutamide, apalutamide and darolutamide, in the management of advanced prostate cancer, and data on its use in Asian patients, in order to extrapolate these findings to the Southeast Asian patient population. There are some differences in the molecular features between the NHTs, which influenced their respective permeabilities through the blood-brain barrier. The Asian sub-analyses of the landmark studies of each NHT were limited. The primary endpoints of the Asian sub-analyses generally reflect the efficacy outcomes of the respective landmark study. Hypertension, fatigue, musculoskeletal disorders, rash, and hot flushes were among the common toxicities observed in Asian patients. Real-world data on AA in the Asian setting is favourable, but data is limited for enzalutamide, apalutamide and darolutamide. Based on the sub-analyses and real-world data, the efficacy and safety of NHTs in the Asian patients showed a similar trend to the respective landmark studies. The lack of clinical trials in the Southeast Asian region hampers the ability to make a robust conclusion on any specific efficacy or safety differences that may be present; clinicians must assume that the broader Asian sub-analyses and real-world data reflects Southeast Asian patients' outcomes.
Keywords
Advanced prostate cancer, Southeast Asia, New generation androgen receptor-axis targeted therapies, Abiraterone acetate, Enzalutamide, Apalutamide, Darolutamide
Divisions
oncology,surgerydept
Funders
Johnson & Johnson Malaysia
Publication Title
BMC Urology
Volume
23
Issue
1
Publisher
BioMed Central
Publisher Location
CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND